The platelet contribution to cancer progression

Journal of Thrombosis and Haemostasis

Volumn 9, Issue 2, 2011, Pages 237-249

  Bambace, N M ^a   Holmes, C E ^a  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

Angiogenesis; Cancer; Metastases; Platelets; TCIPA

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; BASIC FIBROBLAST GROWTH FACTOR; BENORILATE; CATHEPSIN B; CLOPIDOGREL; DIPYRIDAMOLE; GELATINASE; GELATINASE A; GLYCOPROTEIN IB; GLYCOPROTEIN IIB; GLYCOPROTEIN IIIA; GLYCOPROTEIN VI; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEPARANASE; INTERLEUKIN 1; INTERLEUKIN 6; MOPIDAMOL; PADGEM PROTEIN; PROTEINASE ACTIVATED RECEPTOR 1; PROTEINASE ACTIVATED RECEPTOR 4; PURINERGIC P2Y1 RECEPTOR; PURINERGIC P2Y12 RECEPTOR; SEROTONIN; TAMOXIFEN; THROMBIN; THROMBOXANE A2; THROMBOXANE A2 RECEPTOR; VASCULOTROPIN;

ANGIOGENESIS; BREAST CANCER; CANCER CELL; CANCER GROWTH; CELL PROLIFERATION; COLON CANCER; COLORECTAL CANCER; CYTOKINE RELEASE; DRUG MECHANISM; HEART MUSCLE ISCHEMIA; HEMOSTASIS; HUMAN; IMMUNE RESPONSE; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MEGAKARYOCYTE; METASTASIS; NONHUMAN; OVARY CANCER; PLATELET MICROPARTICLE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; REVIEW; SARCOMA CELL; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE FUNCTION; THROMBOCYTE STRUCTURE; THROMBOCYTOPENIA; THROMBOCYTOPOIESIS; THROMBOCYTOSIS;

BLOOD PLATELETS; DISEASE PROGRESSION; HUMANS; NEOPLASMS; PLATELET ACTIVATION; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS;

EID: 79251577730     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2010.04131.x     Document Type: Review

References (175)

1. Sierko E, Wojtukiewicz MZ. Platelets and angiogenesis in malignancy. Semin Thromb Hemost 2004; 30: 95-108.
2. Hoffman R. Hematology: Basic Principles and Practice. Philadelphia, PA: Churchill Livingstone/Elsevier, 2009.
3. Ma YQ, Qin J, Plow EF. Platelet integrin alpha(IIb)beta(3): activation mechanisms. J Thromb Haemost 2007; 5: 1345-52.
4. Offermanns S. Activation of platelet function through G protein-coupled receptors. Circ Res 2006; 99: 1293-304.
5. Reed GL, Fitzgerald ML, Polgar J. Molecular mechanisms of platelet exocytosis: insights into the "secrete" life of thrombocytes. Blood 2000; 96: 3334-42.
6. Coppinger JA, Cagney G, Toomey S, Kislinger T, Belton O, McRedmond JP, Cahill DJ, Emili A, Fitzgerald DJ, Maguire PB. Characterization of the proteins released from activated platelets leads to localization of novel platelet proteins in human atherosclerotic lesions. Blood 2004; 103: 2096-104.
7. Zhuge Y, Zhou JY, Yang GD, Zu DL, Xu XL, Tian MQ, Lu GH. Activated changes of platelet ultra microstructure and plasma granule membrane protein 140 in patients with non-small cell lung cancer. Chin Med J (Engl) 2009; 122: 1026-31.
8. Bastida E, Ordinas A, Giardina SL, Jamieson GA. Differentiation of platelet-aggregating effects of human tumor cell lines based on inhibition studies with apyrase, hirudin, and phospholipase. Cancer Res 1982; 42: 4348-52.
9. Grignani G, Pacchiarini L, Ricetti MM, Dionigi P, Jemos V, Zucchella M, Fratino P. Mechanisms of platelet activation by cultured human cancer cells and cells freshly isolated from tumor tissues. Invasion Metastasis 1989; 9: 298-309.
10. Pinto S, Gori L, Gallo O, Boccuzzi S, Paniccia R, Abbate R. Increased thromboxane A2 production at primary tumor site in metastasizing squamous cell carcinoma of the larynx. Prostaglandins Leukot Essent Fatty Acids 1993; 49: 527-30.
11. Zucchella M, Dezza L, Pacchiarini L, Meloni F, Tacconi F, Bonomi E, Grignani G, Notario A. Human tumor cells cultured "in vitro" activate platelet function by producing ADP or thrombin. Haematologica 1989; 74: 541-5.
12. Bastida E, Ordinas A, Jamieson GA. Differing platelet aggregating effects by two tumor cell lines: absence of role for platelet-derived ADP. Am J Hematol 1981; 11: 367-78.
13. Yazaki T, Inage H, Iizumi T, Koyama A, Kanoh S, Koiso K, Narita M, Tojo S. Studies on platelet function in patients with prostatic cancer. Preliminary report. Urology 1987; 30: 60-3.
14. Ferriere JP, Bernard D, Legros M, Chassagne J, Chollet P, Gaillard G, Plagne R. beta-thromboglobulin in patients with breast cancer. Am J Hematol 1985; 19: 47-53.
15. Milroy R, Douglas JT, Campbell J, Carter R, Lowe GD, Banham SW. Abnormal haemostasis in small cell lung cancer. Thorax 1988; 43: 978-81.
16. Prisco D, Paniccia R, Coppo M, Filippini M, Francalanci I, Brunelli T, Comeglio P, Abbate R. Platelet activation and platelet lipid composition in pulmonary cancer. Prostaglandins Leukot Essent Fatty Acids 1995; 53: 65-8.
17. Abbasciano V, Bianchi MP, Trevisani L, Sartori S, Gilli G, Zavagli G. Platelet activation and fibrinolysis in large bowel cancer. Oncology 1995; 52: 381-4.
18. Taddeo U, Tumaini P, Abbasciano V, Ballerini G. [Platelet activation in thrombotic and prethrombotic venous pathology]. Minerva Cardioangiol 1985; 33: 273-7.
19. Wehmeier A, Tschope D, Esser J, Menzel C, Nieuwenhuis HK, Schneider W. Circulating activated platelets in myeloproliferative disorders. Thromb Res 1991; 61: 271-8.
20. Wojtukiewicz MZ, Sierko E, Rak J. Contribution of the hemostatic system to angiogenesis in cancer. Semin Thromb Hemost 2004; 30: 5-20.
21. Grignani G, Jamieson GA. Platelets in tumor metastasis: generation of adenosine diphosphate by tumor cells is specific but unrelated to metastatic potential. Blood 1988; 71: 844-9.
22. Holme R, Oftebro R, Hovig T. In vitro interaction between cultured cells and human blood platelets. Thromb Haemost 1978; 40: 89-102.
23. Gasic GJ, Gasic TB, Stewart CC. Antimetastatic effects associated with platelet reduction. Proc Natl Acad Sci USA 1968; 61: 46-52.
24. Karpatkin S, Pearlstein E. Role of platelets in tumor cell metastases. Ann Intern Med 1981; 95: 636-41.
25. Tranum BL, Haut A. Thrombocytosis: platelet kinetics in neoplasia. J Lab Clin Med 1974; 84: 615-9.
26. Ikeda M, Furukawa H, Imamura H, Shimizu J, Ishida H, Masutani S, Tatsuta M, Satomi T. Poor prognosis associated with thrombocytosis in patients with gastric cancer. Ann Surg Oncol 2002; 9: 287-91.
27. Monreal M, Fernandez-Llamazares J, Pinol M, Julian JF, Broggi M, Escola D, Abad A. Platelet count and survival in patients with colorectal cancer--a preliminary study. Thromb Haemost 1998; 79: 916-8.
28. Symbas NP, Townsend MF, El-Galley R, Keane TE, Graham SD, Petros JA. Poor prognosis associated with thrombocytosis in patients with renal cell carcinoma. BJU Int 2000; 86: 203-7. bju792 [pii].
29. Gucer F, Moser F, Tamussino K, Reich O, Haas J, Arikan G, Petru E, Winter R. Thrombocytosis as a prognostic factor in endometrial carcinoma. Gynecol Oncol 1998; 70: 210-4.
30. Menczer J, Schejter E, Geva D, Ginath S, Zakut H. Ovarian carcinoma associated thrombocytosis. Correlation with prognostic factors and with survival. Eur J Gynaecol Oncol 1998; 19: 82-4.
31. Lopes A, Daras V, Cross PA, Robertson G, Beynon G, Monaghan JM. Thrombocytosis as a prognostic factor in women with cervical cancer. Cancer 1994; 74: 90-2.
32. Zeimet AG, Marth C, Muller-Holzner E, Daxenbichler G, Dapunt O. Significance of thrombocytosis in patients with epithelial ovarian cancer. Am J Obstet Gynecol 1994; 170: 549-54.
33. Salgado R, Vermeulen PB, Benoy I, Weytjens R, Huget P, van Marck E, Dirix LY. Platelet number and interleukin-6 correlate with VEGF but not with bFGF serum levels of advanced cancer patients. Br J Cancer 1999; 80: 892-7.
34. Gastl G, Plante M, Finstad CL, Wong GY, Federici MG, Bander NH, Rubin SC. High IL-6 levels in ascitic fluid correlate with reactive thrombocytosis in patients with epithelial ovarian cancer. Br J Haematol 1993; 83: 433-41.
35. Kaser A, Brandacher G, Steurer W, Kaser S, Offner FA, Zoller H, Theurl I, Widder W, Molnar C, Ludwiczek O, Atkins MB, Mier JW, Tilg H. Interleukin-6 stimulates thrombopoiesis through thrombopoietin: role in inflammatory thrombocytosis. Blood 2001; 98: 2720-5.
36. Estrov Z, Talpaz M, Mavligit G, Pazdur R, Harris D, Greenberg SM, Kurzrock R. Elevated plasma thrombopoietic activity in patients with metastatic cancer-related thrombocytosis. Am J Med 1995; 98: 551-8.
37. Higashihara M, Sunaga S, Tange T, Oohashi H, Kurokawa K. Increased secretion of interleukin-6 in malignant mesothelioma cells from a patient with marked thrombocytosis. Cancer 1992; 70: 2105-8.
38. Suzuki A, Takahashi T, Nakamura K, Tsuyuoka R, Okuno Y, Enomoto T, Fukumoto M, Imura H. Thrombocytosis in patients with tumors producing colony-stimulating factor. Blood 1992; 80: 2052-9.
39. Wickenhauser C, Lorenzen J, Thiele J, Hillienhof A, Jungheim K, Schmitz B, Hansmann ML, Fischer R. Secretion of cytokines (interleukins-1 alpha, -3, and -6 and granulocyte-macrophage colony-stimulating factor) by normal human bone marrow megakaryocytes. Blood 1995; 85: 685-91.
40. Jones CL, Witte DP, Feller MJ, Fugman DA, Dorn GW II, Lieberman MA. Response of a human megakaryocytic cell line to thrombin: increase in intracellular free calcium and mitogen release. Biochim Biophys Acta 1992; 1136: 272-82.
41. Mohle R, Green D, Moore MA, Nachman RL, Rafii S. Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets. Proc Natl Acad Sci USA 1997; 94: 663-8.
42. Avraham H, Banu N, Scadden DT, Abraham J, Groopman JE. Modulation of megakaryocytopoiesis by human basic fibroblast growth factor. Blood 1994; 83: 2126-32.
43. Casella I, Feccia T, Chelucci C, Samoggia P, Castelli G, Guerriero R, Parolini I, Petrucci E, Pelosi E, Morsilli O, Gabbianelli M, Testa U, Peschle C. Autocrine-paracrine VEGF loops potentiate the maturation of megakaryocytic precursors through Flt1 receptor. Blood 2003; 101: 1316-23.
44. Sarach MA, Rovasio RA, Eynard AR. Platelet factors induce chemotactic migration of murine mammary adenocarcinoma cells with different metastatic capabilities. Int J Exp Pathol 1993; 74: 511-7.
45. Poggi A, Vicenzi E, Cioce V, Wasteson A. Platelet contribution to cancer cell growth and migration: the role of platelet growth factors. Haemostasis 1988; 18: 18-28.
46. Belloc C, Lu H, Soria C, Fridman R, Legrand Y, Menashi S. The effect of platelets on invasiveness and protease production of human mammary tumor cells. Int J Cancer 1995; 60: 413-7.
47. Lewalle JM, Castronovo V, Goffinet G, Foidart JM. Malignant cell attachment to endothelium of ex vivo perfused human umbilical vein. Modulation by platelets, plasma and fibronectin. Thromb Res 1991; 62: 287-98.
48. Felding-Habermann B, O'Toole TE, Smith JW, Fransvea E, Ruggeri ZM, Ginsberg MH, Hughes PE, Pampori N, Shattil SJ, Saven A, Mueller BM. Integrin activation controls metastasis in human breast cancer. Proc Natl Acad Sci USA 2001; 98: 1853-8.
49. Jones DS, Wallace AC, Fraser EE. Sequence of events in experimental metastases of Walker 256 tumor: light, immunofluorescent, and electron microscopic observations. J Natl Cancer Inst 1971; 46: 493-504.
50. Holmes CE, Levis JE, Ornstein DL. Activated platelets enhance ovarian cancer cell invasion in a cellular model of metastasis. Clin Exp Metastasis 2009; 26: 653-61.
51. Boucharaba A, Serre CM, Gres S, Saulnier-Blache JS, Bordet JC, Guglielmi J, Clezardin P, Peyruchaud O. Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer. J Clin Invest 2004; 114: 1714-25.
52. Assoian RK, Sporn MB. Type beta transforming growth factor in human platelets: release during platelet degranulation and action on vascular smooth muscle cells. J Cell Biol 1986; 102: 1217-23.
53. Verheul HM, Hoekman K, Luykx-de Bakker S, Eekman CA, Folman CC, Broxterman HJ, Pinedo HM. Platelet: transporter of vascular endothelial growth factor. Clin Cancer Res 1997; 3: 2187-90.
54. Dubernard V, Arbeille BB, Lemesle MB, Legrand C. Evidence for an alpha-granular pool of the cytoskeletal protein alpha-actinin in human platelets that redistributes with the adhesive glycoprotein thrombospondin-1 during the exocytotic process. Arterioscler Thromb Vasc Biol 1997; 17: 2293-305.
55. Kaplan KL, Broekman MJ, Chernoff A, Lesznik GR, Drillings M. Platelet alpha-granule proteins: studies on release and subcellular localization. Blood 1979; 53: 604-18.
56. Sawicki G, Salas E, Murat J, Miszta-Lane H, Radomski MW. Release of gelatinase A during platelet activation mediates aggregation. Nature 1997; 386: 616-9.
57. Menashi S, He L, Soria C, Soria J, Thomaidis A, Legrand Y. Modulation of endothelial cells fibrinolytic activity by platelets. Thromb Haemost 1991; 65: 77-81.
58. Huang S, van Arsdall M, Tedjarati S, McCarty M, Wu W, Langley R, Fidler IJ. Contributions of stromal metalloproteinase-9 to angiogenesis and growth of human ovarian carcinoma in mice. J Natl Cancer Inst 2002; 94: 1134-42.
59. Karpatkin S, Pearlstein E, Ambrogio C, Coller BS. Role of adhesive proteins in platelet tumor interaction in vitro and metastasis formation in vivo. J Clin Invest 1988; 81: 1012-9.
60. Karpatkin S, Ambrogio C, Pearlstein E. The role of tumor-induced platelet aggregation, platelet adhesion and adhesive proteins in tumor metastasis. Prog Clin Biol Res 1988; 283: 585-606.
61. Shau H, Roth MD, Golub SH. Regulation of natural killer function by nonlymphoid cells. Nat Immun 1993; 12: 235-49.
62. Philippe C, Philippe B, Fouqueray B, Perez J, Lebret M, Baud L. Protection from tumor necrosis factor-mediated cytolysis by platelets. Am J Pathol 1993; 143: 1713-23.
63. Timar J, Tovari J, Raso E, Meszaros L, Bereczky B, Lapis K. Platelet-mimicry of cancer cells: epiphenomenon with clinical significance. Oncology 2005; 69: 185-201.
64. Kopp HG, Placke T, Salih HR. Platelet-derived transforming growth factor-beta down-regulates NKG2D thereby inhibiting natural killer cell antitumor reactivity. Cancer Res 2009; 69: 7775-83. 0008-5472.CAN-09-2123 [pii]. Doi:
65. Malik AB. Pulmonary microembolism. Physiol Rev 1983; 63: 1114-207.
66. Jurasz P, Alonso-Escolano D, Radomski MW. Platelet--cancer interactions: mechanisms and pharmacology of tumour cell-induced platelet aggregation. Br J Pharmacol 2004; 143: 819-26.
67. Fabre JE, Nguyen M, Latour A, Keifer JA, Audoly LP, Coffman TM, Koller BH. Decreased platelet aggregation, increased bleeding time and resistance to thromboembolism in P2Y1-deficient mice. Nat Med 1999; 5: 1199-202.
68. Boukerche H, Berthier-Vergnes O, Penin F, Tabone E, Lizard G, Bailly M, McGregor JL. Human melanoma cell lines differ in their capacity to release ADP and aggregate platelets. Br J Haematol 1994; 87: 763-72.
69. Bastida E, Escolar G, Almirall L, Ordinas A. Platelet activation induced by a human neuroblastoma tumor cell line is reduced by prior administration of ticlopidine. Thromb Haemost 1986; 55: 333-7.
70. Dorsam RT, Kunapuli SP. Central role of the P2Y12 receptor in platelet activation. J Clin Invest 2004; 113: 340-5.
71. Alonso-Escolano D, Strongin AY, Chung AW, Deryugina EI, Radomski MW. Membrane type-1 matrix metalloproteinase stimulates tumour cell-induced platelet aggregation: role of receptor glycoproteins. Br J Pharmacol 2004; 141: 241-52.
72. Haralabopoulos GC, Grant DS, Kleinman HK, Maragoudakis ME. Thrombin promotes endothelial cell alignment in Matrigel in vitro and angiogenesis in vivo. Am J Physiol 1997; 273: C239-45.
73. Wojtukiewicz MZ, Zacharski LR, Memoli VA, Kisiel W, Kudryk BJ, Rousseau SM, Stump DC. Fibrinogen-fibrin transformation in situ in renal cell carcinoma. Anticancer Res 1990; 10: 579-82.
74. Zacharski LR, Memoli VA, Ornstein DL, Rousseau SM, Kisiel W, Kudryk BJ. Tumor cell procoagulant and urokinase expression in carcinoma of the ovary. J Natl Cancer Inst 1993; 85: 1225-30.
75. Wojtukiewicz MZ, Zacharski LR, Memoli VA, Kisiel W, Kudryk BJ, Rousseau SM, Stump DC. Malignant melanoma. Interaction with coagulation and fibrinolysis pathways in situ. Am J Clin Pathol 1990; 93: 516-21.
76. Wojtukiewicz MZ, Tang DG, Nelson KK, Walz DA, Diglio CA, Honn KV. Thrombin enhances tumor cell adhesive and metastatic properties via increased alpha IIb beta 3 expression on the cell surface. Thromb Res 1992; 68: 233-45.
77. Zhou H, Gabazza EC, Takeya H, Deguchi H, Urano H, Adachi Y, Suzuki K. Prothrombin and its derivatives stimulate motility of melanoma cells. Thromb Haemost 1998; 80: 407-12.
78. Tsopanoglou NE, Maragoudakis ME. Role of thrombin in angiogenesis and tumor progression. Semin Thromb Hemost 2004; 30: 63-9.
79. Yamahata H, Takeshima H, Kuratsu J, Sarker KP, Tanioka K, Wakimaru N, Nakata M, Kitajima I, Maruyama I. The role of thrombin in the neo-vascularization of malignant gliomas: an intrinsic modulator for the up-regulation of vascular endothelial growth factor. Int J Oncol 2002; 20: 921-8.
80. Olas B, Mielicki WP, Wachowicz B, Krajewski T. Cancer procoagulant stimulates platelet adhesion. Thromb Res 1999; 94: 199-203.
81. Honn KV, Cavanaugh P, Evens C, Taylor JD, Sloane BF. Tumor cell-platelet aggregation: induced by cathepsin B-like proteinase and inhibited by prostacyclin. Science 1982; 217: 540-2.
82. Jurasz P, Sawicki G, Duszyk M, Sawicka J, Miranda C, Mayers I, Radomski MW. Matrix metalloproteinase 2 in tumor cell-induced platelet aggregation: regulation by nitric oxide. Cancer Res 2001; 61: 376-82.
83. Deryugina EI, Quigley JP. Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev 2006; 25: 9-34.
84. Pacchiarini L, Zucchella M, Milanesi G, Tacconi F, Bonomi E, Canevari A, Grignani G. Thromboxane production by platelets during tumor cell-induced platelet activation. Invasion Metastasis 1991; 11: 102-9.
85. Erpenbeck L, Schon MP. Deadly allies: the fatal interplay between platelets and metastasizing cancer cells. Blood 2010; 115: 3427-36.
86. Grossi IM, Fitzgerald LA, Kendall A, Taylor JD, Sloane BF, Honn KV. Inhibition of human tumor cell induced platelet aggregation by antibodies to platelet glycoproteins Ib and IIb/IIIa. Proc Soc Exp Biol Med 1987; 186: 378-83.
87. Amirkhosravi A, Amaya M, Siddiqui F, Biggerstaff JP, Meyer TV, Francis JL. Blockade of GpIIb/IIIa inhibits the release of vascular endothelial growth factor (VEGF) from tumor cell-activated platelets and experimental metastasis. Platelets 1999; 10: 285-92.
88. Nierodzik ML, Klepfish A, Karpatkin S. Role of platelet integrin GPIIb-GPIIIa, fibronectin, von Willebrand factor, and thrombin in platelet-tumor interaction in vitro and metastasis in vivo. Semin Hematol 1994; 31: 278-88.
89. Bastida E, Almirall L, Ordinas A. Tumor-cell-induced platelet aggregation is a glycoprotein-dependent and lipoxygenase-associated process. Int J Cancer 1987; 39: 760-3.
90. Trikha M, Zhou Z, Timar J, Raso E, Kennel M, Emmell E, Nakada MT. Multiple roles for platelet GPIIb/IIIa and alphavbeta3 integrins in tumor growth, angiogenesis, and metastasis. Cancer Res 2002; 62: 2824-33.
91. Erpenbeck L, Nieswandt B, Schon M, Pozgajova M, Schon MP. Inhibition of platelet GPIb alpha and promotion of melanoma metastasis. J Invest Dermatol 2010; 130: 576-86. jid2009278 [pii]. Doi:
92. Jain S, Zuka M, Liu J, Russell S, Dent J, Guerrero JA, Forsyth J, Maruszak B, Gartner TK, Felding-Habermann B, Ware J. Platelet glycoprotein Ib alpha supports experimental lung metastasis. Proc Natl Acad Sci USA 2007; 104: 9024-8.
93. Jain S, Russell S, Ware J. Platelet glycoprotein VI facilitates experimental lung metastasis in syngenic mouse models. J Thromb Haemost 2009; 7: 1713-7.
94. Yang J, Furie BC, Furie B. The biology of P-selectin glycoprotein ligand-1: its role as a selectin counterreceptor in leukocyte-endothelial and leukocyte-platelet interaction. Thromb Haemost 1999; 81: 1-7.
95. Borsig L, Wong R, Hynes RO, Varki NM, Varki A. Synergistic effects of L- and P-selectin in facilitating tumor metastasis can involve non-mucin ligands and implicate leukocytes as enhancers of metastasis. Proc Natl Acad Sci USA 2002; 99: 2193-8.
96. Mannori G, Crottet P, Cecconi O, Hanasaki K, Aruffo A, Nelson RM, Varki A, Bevilacqua MP. Differential colon cancer cell adhesion to E-, P-, and L-selectin: role of mucin-type glycoproteins. Cancer Res 1995; 55: 4425-31.
97. Ludwig RJ, Boehme B, Podda M, Henschler R, Jager E, Tandi C, Boehncke WH, Zollner TM, Kaufmann R, Gille J. Endothelial P-selectin as a target of heparin action in experimental melanoma lung metastasis. Cancer Res 2004; 64: 2743-50.
98. Kim YJ, Borsig L, Varki NM, Varki A. P-selectin deficiency attenuates tumor growth and metastasis. Proc Natl Acad Sci USA 1998; 95: 9325-30.
99. Stone JP, Wagner DD. P-selectin mediates adhesion of platelets to neuroblastoma and small cell lung cancer. J Clin Invest 1993; 92: 804-13.
100. Varki A, Varki NM. P-selectin, carcinoma metastasis and heparin: novel mechanistic connections with therapeutic implications. Braz J Med Biol Res 2001; 34: 711-7.
101. Aharon A, Brenner B. Microparticles, thrombosis and cancer. Best Pract Res Clin Haematol 2009; 22: 61-9.
102. Barry OP, FitzGerald GA. Mechanisms of cellular activation by platelet microparticles. Thromb Haemost 1999; 82: 794-800.
103. Barry OP, Pratico D, Savani RC, FitzGerald GA. Modulation of monocyte-endothelial cell interactions by platelet microparticles. J Clin Invest 1998; 102: 136-44.
104. Barry OP, Pratico D, Lawson JA, FitzGerald GA. Transcellular activation of platelets and endothelial cells by bioactive lipids in platelet microparticles. J Clin Invest 1997; 99: 2118-27.
105. Janowska-Wieczorek A, Marquez-Curtis LA, Wysoczynski M, Ratajczak MZ. Enhancing effect of platelet-derived microvesicles on the invasive potential of breast cancer cells. Transfusion 2006; 46: 1199-209.
106. Brill A, Dashevsky O, Rivo J, Gozal Y, Varon D. Platelet-derived microparticles induce angiogenesis and stimulate post-ischemic revascularization. Cardiovasc Res 2005; 67: 30-8.
107. Janowska-Wieczorek A, Wysoczynski M, Kijowski J, Marquez-Curtis L, Machalinski B, Ratajczak J, Ratajczak MZ. Microvesicles derived from activated platelets induce metastasis and angiogenesis in lung cancer. Int J Cancer 2005; 113: 752-60.
108. Dashevsky O, Varon D, Brill A. Platelet-derived microparticles promote invasiveness of prostate cancer cells via upregulation of MMP-2 production. Int J Cancer 2009; 124: 1773-7.
109. Pinedo HM, Verheul HM, D'Amato RJ, Folkman J. Involvement of platelets in tumour angiogenesis? Lancet 1998; 352: 1775-7.
110. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285: 1182-6.
111. Coussens LM, Raymond WW, Bergers G, Laig-Webster M, Behrendtsen O, Werb Z, Caughey GH, Hanahan D. Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. Genes Dev 1999; 13: 1382-97.
112. Fukumura D, Xavier R, Sugiura T, Chen Y, Park EC, Lu N, Selig M, Nielsen G, Taksir T, Jain RK, Seed B. Tumor induction of VEGF promoter activity in stromal cells. Cell 1998; 94: 715-25.
113. Hlatky L, Tsionou C, Hahnfeldt P, Coleman CN. Mammary fibroblasts may influence breast tumor angiogenesis via hypoxia-induced vascular endothelial growth factor up-regulation and protein expression. Cancer Res 1994; 54: 6083-6.
114. Polverini PJ, Cotran PS, Gimbrone MA Jr, Unanue ER. Activated macrophages induce vascular proliferation. Nature 1977; 269: 804-6.
115. DiPietro LA, Polverini PJ. Angiogenic macrophages produce the angiogenic inhibitor thrombospondin 1. Am J Pathol 1993; 143: 678-84.
116. Holmes CE, Huang JC, Pace TR, Howard AB, Muss HB. Tamoxifen and aromatase inhibitors differentially affect vascular endothelial growth factor and endostatin levels in women with breast cancer. Clin Cancer Res 2008; 14: 3070-6.
117. Peterson JE, Zurakowski D, Italiano JE Jr, Michel LV, Fox L, Klement GL, Folkman J. Normal ranges of angiogenesis regulatory proteins in human platelets. Am J Hematol 2010; 85: 487-93.
118. Jelkmann W. Pitfalls in the measurement of circulating vascular endothelial growth factor. Clin Chem 2001; 47: 617-23.
119. Wojtukiewicz MZ, Sierko E, Klement P, Rak J. The hemostatic system and angiogenesis in malignancy. Neoplasia 2001; 3: 371-84.
120. Zaslavsky A, Baek KH, Lynch RC, Short S, Grillo J, Folkman J, Italiano JE Jr, Ryeom S. Platelet-derived thrombospondin-1 is a critical negative regulator and potential.biomarker of angiogenesis. Blood 2010; 115: 4605-13.
121. Pietramaggiori G, Scherer SS, Cervi D, Klement G, Orgill DP. Tumors stimulate platelet delivery of angiogenic factors in vivo: an unexpected benefit. Am J Pathol 2008; 173: 1609-16.
122. Italiano JE Jr, Richardson JL, Patel-Hett S, Battinelli E, Zaslavsky A, Short S, Ryeom S, Folkman J, Klement GL. Angiogenesis is regulated by a novel mechanism: pro- and antiangiogenic proteins are organized into separate platelet alpha granules and differentially released. Blood 2008; 111: 1227-33.
123. Ma L, Perini R, McKnight W, Dicay M, Klein A, Hollenberg MD, Wallace JL. Proteinase-activated receptors 1 and 4 counter-regulate endostatin and VEGF release from human platelets. Proc Natl Acad Sci USA 2005; 102: 216-20.
124. Bambace NM, Levis JE, Holmes CE. The effect of P2Y-mediated platelet activation on the release of VEGF and endostatin from platelets. Platelets 2010; 21: 85-93.
125. Daly ME, Makris A, Reed M, Lewis CE. Hemostatic regulators of tumor angiogenesis: a source of antiangiogenic agents for cancer treatment? J Natl Cancer Inst 2003; 95: 1660-73.
126. Klement GL, Yip TT, Cassiola F, Kikuchi L, Cervi D, Podust V, Italiano JE, Wheatley E, Abou-Slaybi A, Bender E, Almog N, Kieran MW, Folkman J. Platelets actively sequester angiogenesis regulators. Blood 2009; 113: 2835-42.
127. Salgado R, Benoy I, Weytjens R, van Bockstaele D, van Marck E, Huget P, Hoylaerts M, Vermeulen P, Dirix LY. Arterio-venous gradients of IL-6, plasma and serum VEGF and D-dimers in human cancer. Br J Cancer 2002; 87: 1437-44.
128. Pipili-Synetos E, Papadimitriou E, Maragoudakis ME. Evidence that platelets promote tube formation by endothelial cells on matrigel. Br J Pharmacol 1998; 125: 1252-7.
129. Rhee JS, Black M, Schubert U, Fischer S, Morgenstern E, Hammes HP, Preissner KT. The functional role of blood platelet components in angiogenesis. Thromb Haemost 2004; 92: 394-402.
130. Kisucka J, Butterfield CE, Duda DG, Eichenberger SC, Saffaripour S, Ware J, Ruggeri ZM, Jain RK, Folkman J, Wagner DD. Platelets and platelet adhesion support angiogenesis while preventing excessive hemorrhage. Proc Natl Acad Sci USA 2006; 103: 855-60.
131. Manegold PC, Hutter J, Pahernik SA, Messmer K, Dellian M. Platelet-endothelial interaction in tumor angiogenesis and microcirculation. Blood 2003; 101: 1970-6.
132. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420: 860-7.
133. White N, Ryten M, Clayton E, Butler P, Burnstock G. P2Y purinergic receptors regulate the growth of human melanomas. Cancer Lett 2005; 224: 81-91.
134. Rumjahn SM, Yokdang N, Baldwin KA, Thai J, Buxton IL. Purinergic regulation of vascular endothelial growth factor signaling in angiogenesis. Br J Cancer 2009; 100: 1465-70.
135. Rumjahn SM, Javed MA, Wong N, Law WE, Buxton IL. Purinergic regulation of angiogenesis by human breast carcinoma-secreted nucleoside diphosphate kinase. Br J Cancer 2007; 97: 1372-80.
136. Ruf W, Mueller BM. Thrombin generation and the pathogenesis of cancer. Semin Thromb Hemost 2006; 32(Suppl 1): 61-8.
137. Schaffner F, Ruf W. Tissue factor and PAR2 signaling in the tumor microenvironment. Arterioscler Thromb Vasc Biol 2009; 29: 1999-2004.
138. Kerr BA, Miocinovic R, Smith AK, Klein EA, Byzova TV. Comparison of tumor and microenvironment secretomes in plasma and in platelets during prostate cancer growth in a xenograft model. Neoplasia 2010; 12: 388-96.
139. Cervi D, Yip TT, Bhattacharya N, Podust VN, Peterson J, Abou-Slaybi A, Naumov GN, Bender E, Almog N, Italiano JE Jr, Folkman J, Klement GL. Platelet-associated PF-4 as a biomarker of early tumor growth. Blood 2008; 111: 1201-7.
140. Ho-Tin-Noe B, Goerge T, Wagner DD. Platelets: guardians of tumor vasculature. Cancer Res 2009; 69: 5623-6.
141. Ho-Tin-Noe B, Goerge T, Cifuni SM, Duerschmied D, Wagner DD. Platelet granule secretion continuously prevents intratumor hemorrhage. Cancer Res 2008; 68: 6851-8.
142. Ho-Tin-Noe B, Carbo C, Demers M, Cifuni SM, Goerge T, Wagner DD. Innate immune cells induce hemorrhage in tumors during thrombocytopenia. Am J Pathol 2009; 175: 1699-708.
143. Washington AV, Gibot S, Acevedo I, Gattis J, Quigley L, Feltz R, De La Mota A, Schubert RL, Gomez-Rodriguez J, Cheng J, Dutra A, Pak E, Chertov O, Rivera L, Morales J, Lubkowski J, Hunter R, Schwartzberg PL, McVicar DW. TREM-like transcript-1 protects against inflammation-associated hemorrhage by facilitating platelet aggregation in mice and humans. J Clin Invest 2009; 119: 1489-501.
144. Hirahashi J, Hishikawa K, Kaname S, Tsuboi N, Wang Y, Simon DI, Stavrakis G, Shimosawa T, Xiao L, Nagahama Y, Suzuki K, Fujita T, Mayadas TN. Mac-1 (CD11b/CD18) links inflammation and thrombosis after glomerular injury. Circulation 2009; 120: 1255-65.
145. Goerge T, Ho-Tin-Noe B, Carbo C, Benarafa C, Remold-O'Donnell E, Zhao BQ, Cifuni SM, Wagner DD. Inflammation induces hemorrhage in thrombocytopenia. Blood 2008; 111: 4958-64.
146. Zacharski LR, Donati MB. Registry of clinical trials of antithrombotic drugs in cancer. The Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Subcommittee on Hemostasis and Malignancy. Thromb Haemost 1989; 61: 526-8.
147. Zacharski LR, Donati MB, Rickles FR. Registry of clinical trials of antithrombotic drugs in cancer: second report. The Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis Subcommittee on Hemostasis and Malignancy. Thromb Haemost 1993; 70: 357-60.
148. Nieminen U, Kauppila A, Gronroos M, Kuoppala T, Vayrynen M. Placebo-controlled study on the efficacy of the pyrimido-pyrimidine derivative RA 233 in ovarian cancer. Gynecol Oncol 1990; 36: 226-31.
149. Zacharski LR, Cornell CJ, Haakenson CM, Ballards HS, Crum ED, Johnson GJ, Levine J, Hong WK, O'Donnell JF, Schilsky RL, Ringemberg QS, Robert F, Spaulding MB, Tornyos K, William C, Zucker S. Effect of RA-233 (Mopidamole) on survival in carcinoma of the lung and colon. Final report of the VA Cooperative Study 188. J Natl Cancer Inst 1988; 80: 9097-141.
150. Lipton A, Harvey HA, Walker B, Dixon R, Valdivia D, Barnes S, Gordon R, White-Hershey D, Bartholomew MJ, Warzawski N, Antle CE. Chemotherapy plus RA233 in the treatment of oat cell lung cancer. Am J Clin Oncol 1989; 12: 259-63.
151. Creagan ET, Twito DI, Johansson SL, Schaid DJ, Johnson PS, Flaum MA, Buroker TR, Geeraerts LH, Veeder MH, Gesme DH Jr. A randomized prospective assessment of recombinant leukocyte A human interferon with or without aspirin in advanced renal adenocarcinoma. J Clin Oncol 1991; 9: 2104-9.
152. Cole BF, Logan RF, Halabi S, Benamouzig R, Sandler RS, Grainge MJ, Chaussade S, Baron JA. Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials. J Natl Cancer Inst 2009; 101: 256-66.
153. Coppinger JA, O'Connor R, Wynne K, Flanagan M, Sullivan M, Maguire PB, Fitzgerald DJ, Cagney G. Moderation of the platelet releasate response by aspirin. Blood 2007; 109: 4786-92.
154. Gasic GJ, Gasic TB, Galanti N, Johnson T, Murphy S. Platelet-tumor-cell interactions in mice. The role of platelets in the spread of malignant disease. Int J Cancer 1973; 11: 704-18.
155. Futakuchi M, Ogawa K, Sano M, Tamano S, Takeshita F, Shirai T. Suppression of lung metastasis by aspirin but not indomethacin in an in vivo model of chemically induced hepatocellular carcinoma. Jpn J Cancer Res 2002; 93: 1175-81.
156. Fontaine E, McShane J, Page R, Shackcloth M, Mediratta N, Carr M, Soorae A, Poullis M. Aspirin and non-small cell lung cancer resections: effect on long-term survival. Eur J Cardiothorac Surg 2010.
157. Holmes MD, Chen WY, Li L, Hertzmark E, Spiegelman D, Hankinson SE. Aspirin intake and survival after breast cancer. J Clin Oncol 2010; 28: 1467-72.
158. Hejna M, Raderer M, Zielinski CC. Inhibition of metastases by anticoagulants. J Natl Cancer Inst 1999; 91: 22-36.
159. Holmes CE, Jasielec JE, Levis JE, Skelly J, Muss HB. The effect of aspirin therapy on circulating vascular endothelial growth factor (VEGF) levels in tamoxifen-treated women. J Clin Oncol 2010; 28: 679.
160. Nierodzik ML, Klepfish A, Karpatkin S. Role of platelets, thrombin, integrin IIb-IIIa, fibronectin and von Willebrand factor on tumor adhesion in vitro and metastasis in vivo. Thromb Haemost 1995; 74: 282-90.
161. Wenzel J, Zeisig R, Fichtner I. Inhibition of metastasis in a murine 4T1 breast cancer model by liposomes preventing tumor cell-platelet interactions. Clin Exp Metastasis 2010; 27: 25-34.
162. Wenzel J, Zeisig R, Fichtner I. Inhibition of breast cancer metastasis by dual liposomes to disturb complex formation. Int J Pharm 2009; 370: 121-8.
163. Mah-Becherel MC, Ceraline J, Deplanque G, Chenard MP, Bergerat JP, Cazenave JP, Klein-Soyer C. Anti-angiogenic effects of the thienopyridine SR 25989 in vitro and in vivo in a murine pulmonary metastasis model. Br J Cancer 2002; 86: 803-10.
164. Franchini M, Montagnana M, Favaloro EJ, Lippi G. The bidirectional relationship of cancer and hemostasis and the potential role of anticoagulant therapy in moderating thrombosis and cancer spread. Semin Thromb Hemost 2009; 35: 644-53.
165. Bakewell SJ, Nestor P, Prasad S, Tomasson MH, Dowland N, Mehrotra M, Scarborough R, Kanter J, Abe K, Phillips D, Weilbaecher KN. Platelet and osteoclast beta3 integrins are critical for bone metastasis. Proc Natl Acad Sci USA 2003; 100: 14205-10.
166. Amirkhosravi A, Mousa SA, Amaya M, Blaydes S, Desai H, Meyer T, Francis JL. Inhibition of tumor cell-induced platelet aggregation and lung metastasis by the oral GpIIb/IIIa antagonist XV454. Thromb Haemost 2003; 90: 549-54.
167. Uluckan O, Eagleton MC, Floyd DH, Morgan EA, Hirbe AC, Kramer M, Dowland N, Prior JL, Piwnica-Worms D, Jeong SS, Chen R, Weilbaecher K. APT102, a novel adpase, cooperates with aspirin to disrupt bone metastasis in mice. J Cell Biochem 2008; 104: 1311-23.
168. Camerer E, Qazi AA, Duong DN, Cornelissen I, Advincula R, Coughlin SR. Platelets, protease-activated receptors, and fibrinogen in hematogenous metastasis. Blood 2004; 104: 397-401.
169. Lipton A, Scialla S, Harvey H, Dixon R, Gordon R, Hamilton R, Ramsey H, Weltz M, Heckard R, White D. Adjuvant antiplatelet therapy with aspirin in colo-rectal cancer. J Med 1982; 13: 419-29.
170. Lebeau B, Chastang C, Muir JF, Vincent J, Massin F, Fabre C. No effect of an antiaggregant treatment with aspirin in small cell lung cancer treated with CCAVP16 chemotherapy. Results from a randomized clinical trial of 303 patients. The "Petites Cellules" Group. Cancer 1993; 71: 1741-5.
171. Fontaine E, McShane J, Page R, Shackcloth M, Mediratta N, Carr M, Soorae A, Poullis M. Aspirin and non-small cell lung cancer resections: effect on long-term survival. Eur J Cardiothorac Surg 2010; 38: 21-6.
172. Choe KS, Correa D, Jani AB, Liauw SL. The use of anticoagulants improves biochemical control of localized prostate cancer treated with radiotherapy. Cancer 2010; 116: 1820-6.
173. Powles TJ, Dady PJ, Williams J, Easty GC, Coombes RC. Use of inhibitors of prostaglandin synthesis in patients with breast cancer. Adv Prostaglandin Thromboxane Res 1980; 6: 511-6.
174. Kohne-Wompner CH, Wilke H, Weiss H, Hiddemann W, Schuller J, Lohrmann HP et al. 5-FU, folinic acid (FA) +/- dipyridamole (D) in advanced and progressive colorectal cancer (CC)- a randomised multicenter phase II trial. Proc Am Soc Clin Oncol 1990; 10: 123.
175. Vallejo CT, Rabinovich MG, Perez JE, Rodriguez R, Machiavelli MR, Leone BA, Romero AD, Lacava JA, Cuevas MA, Langhi MJ, et al. High-dose cisplatin with dipyridamole in advanced non-small cell lung cancer. A Grupo Oncologico Cooperativo del Sur study. Am J Clin Oncol 1995; 18: 185-8.